Cipla cuts prices of 3 cancer drugs by up to 64 pct

Thu Nov 8, 2012 1:18pm IST

Related Topics

Stocks

   

REUTERS - Drugmaker Cipla (CIPL.NS) cut prices of three cancer drugs between 50 percent and 64 percent with immediate effect, after it announced similar price cuts for three drugs early this year.

Lung cancer drug Erlocip would cost 9,900 rupees for 30 tablets instead of 27,000 rupees earlier, while breast cancer treatment Docetax would be priced 1,650 rupees instead of 3,300 rupees, Cipla said in a statement on Thursday.

Cipla last month won a case against Roche Holding (ROG.VX), which accused the Indian company of infringing patent on cancer drug Tarceva, which Cipla sells under the brand name Erlocip.

Capegard, another drug to treat metastatic colorectal and colon caner, would be priced 600 rupees for 10 tablets instead of 1,200 rupees, it said. (Reporting by Kaustubh Kulkarni and Manoj Dharra in Mumbai; Editing by Subhranshu Sahu)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Shares Hit Record

Sensex, Nifty rise to second consecutive record high

Sensex surges 500 points on BOJ easing, L&T gains

The BSE Sensex and Nifty surged to record highs for a second consecutive session on Friday after Bank of Japan's surprise expansion of its massive stimulus programme raised hopes for additional foreign inflows, boosting blue-chips such as Larsen & Toubro.  Full Article 

REUTERS SHOWCASE

Wilful Negligence?

Wilful Negligence?

SEBI piles pressure on Sahara to sell overseas hotels  Full Article 

Indian Economy

Indian Economy

India's fiscal deficit in H1 almost 83 pct of full-year target.  Full Article 

M&M Earnings

M&M Earnings

M&M Q2 net profit down 4 percent, hit by poor monsoon.  Full Article 

Ban on E-Cigs?

Ban on E-Cigs?

Govt considers ban on e-cigarettes, sale of single smokes.  Full Article 

Commodities

Commodities

Silver futures in India hit four-year low on global cues.  Full Article 

BOJ Policy

BOJ Policy

BOJ shocks markets with surprise easing as inflation slows.  Full Article 

Shadow Banking

Shadow Banking

China's shadow banking sector growing rapidly, third largest in world - FSB.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage